Stay updated on Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial

Sign up to get notified when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page

  1. Check
    7 days ago
    No Change Detected
  2. Check
    14 days ago
    No Change Detected
  3. Check
    21 days ago
    Change Detected
    Summary
    The footer now displays site revision v3.8.0 instead of v3.7.2.
    Difference
    0.1%
    Check dated 2026-10-31T13:38:12.000Z thumbnail image
  4. Check
    28 days ago
    Change Detected
    Summary
    A sitewide NIH announcement about a transition from “Artificial Intelligence” to “Super Intelligence” terminology appears above the study record.
    Difference
    0.4%
    Check dated 2026-10-24T16:51:02.000Z thumbnail image
  5. Check
    35 days ago
    Change Detected
    Summary
    The footer now identifies the site as running revision v3.7.2 instead of v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-17T16:41:27.000Z thumbnail image
  6. Check
    42 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision identifier changed from v3.7.0 to v3.7.1.
    Difference
    0.1%
    Check dated 2026-10-10T16:57:17.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    A new revision entry v3.7.0 was added to the history and the previous v3.6.6 entry was removed, reflecting an underlying site update rather than changes to the study data.
    Difference
    0.1%
    Check dated 2026-09-19T19:13:21.000Z thumbnail image
  8. Check
    83 days ago
    Change Detected
    Summary
    The page footer revision was updated from v3.6.5 to v3.6.6, indicating a minor update to the page rendering.
    Difference
    0.1%
    Check dated 2026-08-29T20:26:44.000Z thumbnail image

Stay in the know with updates to Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Elranatamab Study in Relapsed/Refractory Multiple Myeloma Clinical Trial page.